Recently, Novo Nordisk received FDA approval for a pill version of Wegovy, making it the first and only oral GLP-1 approved specifically for weight loss
7 Change in protein levels in participants with MASH treated with semaglutide compared with protein levels in healthy volunteers in an independent real-world observational cohort
Very important, if confirmed and generalized. Conflict of interest: "I am a member of the OPEN-Spain expert group which, as can be seen on the website, receives funding from Novo Nordisk"
Nausea, vomiting, diarrhea, abdominal pain, and constipation occur frequently with both formulations, typically emerging during dose escalation and often diminishing over time as patients develop tolerance
Medication adjustments, protein optimization, and resistance training often help move through these phases safely
Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death